Literature DB >> 12955077

Apoptotic and mitogenic stimuli inactivate Rb by differential utilization of p38 and cyclin-dependent kinases.

Niharika Nath1, Sheng Wang, Vicki Betts, Erik Knudsen, Srikumar Chellappan.   

Abstract

Inactivation of the retinoblastoma (Rb) tumor suppressor protein is essential for the G1/S transition during mammalian cell cycle progression. Although Rb is inactivated by phosphorylation by cyclins D and E and their associated kinases during cell cycle progression, we find that Rb is inactivated upon apoptotic stimulation by Fas through the mediation of p38 kinase, independent of cyclins and cyclin-dependent kinases (cdks). Inactivation by p38 kinase coincided with increased phosphorylation of Rb leading to dissociation of E2F and increased transcriptional activity; such p38-mediated changes in Rb function occurred only during Fas stimulation but not mitogenic progression. p38 kinase targets Rb preferentially and had minimal effects on p107 and had no effect on p130 function. We also find that phosphorylation site mutants of Rb (PSM7LP and PSM9-Rb) that cannot be inactivated by cdks can be targeted by Fas and p38 kinase, suggesting that Rb inactivation by these kinases is biochemically and functionally distinct. It appears that Rb inactivation is achieved by different kinase cascades in response to mitogenic and apoptotic signals.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12955077     DOI: 10.1038/sj.onc.1206843

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  13 in total

1.  Nerve growth factor-induced cell cycle reentry in newborn neurons is triggered by p38MAPK-dependent E2F4 phosphorylation.

Authors:  Sandra M Morillo; Erika P Abanto; María J Román; José M Frade
Journal:  Mol Cell Biol       Date:  2012-05-14       Impact factor: 4.272

2.  Posttranslational modifications of the retinoblastoma tumor suppressor protein as determinants of function.

Authors:  James I Macdonald; Frederick A Dick
Journal:  Genes Cancer       Date:  2012-11

Review 3.  The retinoblastoma tumor-suppressor gene, the exception that proves the rule.

Authors:  D W Goodrich
Journal:  Oncogene       Date:  2006-08-28       Impact factor: 9.867

4.  Flavopiridol synergizes with sorafenib to induce cytotoxicity and potentiate antitumorigenic activity in EGFR/HER-2 and mutant RAS/RAF breast cancer model systems.

Authors:  Teddy S Nagaria; Julia L Williams; Charles Leduc; Jeremy A Squire; Peter A Greer; Waheed Sangrar
Journal:  Neoplasia       Date:  2013-08       Impact factor: 5.715

Review 5.  RB1, development, and cancer.

Authors:  Meenalakshmi Chinnam; David W Goodrich
Journal:  Curr Top Dev Biol       Date:  2011       Impact factor: 4.897

6.  A Crosstalk Between Dual-Specific Phosphatases and Dual-Specific Protein Kinases Can Be A Potential Therapeutic Target for Anti-cancer Therapy.

Authors:  Basak Celtikci
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 7.  Small molecule regulators of Rb-E2F pathway as modulators of transcription.

Authors:  Sandeep Singh; Jackie Johnson; Srikumar Chellappan
Journal:  Biochim Biophys Acta       Date:  2010-07-15

8.  Arterialization of a vein graft promotes cell cycle progression through Akt and p38 mitogen-activated protein kinase pathways: impact of the preparation procedure.

Authors:  Ada W Y Chung; Jerry Wong; Honglin Luo; York N Hsiang; Cornelis van Breemen; Elena B Okon
Journal:  Can J Cardiol       Date:  2007-12       Impact factor: 5.223

9.  Transferrin-receptor-mediated iron accumulation controls proliferation and glutamate release in glioma cells.

Authors:  S R Chirasani; D S Markovic; M Synowitz; S A Eichler; P Wisniewski; B Kaminska; A Otto; E Wanker; M Schäfer; P Chiarugi; J C Meier; H Kettenmann; R Glass
Journal:  J Mol Med (Berl)       Date:  2008-12-09       Impact factor: 4.599

10.  p38 phosphorylates Rb on Ser567 by a novel, cell cycle-independent mechanism that triggers Rb-Hdm2 interaction and apoptosis.

Authors:  R B Delston; K A Matatall; Y Sun; M D Onken; J W Harbour
Journal:  Oncogene       Date:  2010-09-27       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.